In all cases, these tests
should be performed only by a physician knowledgeable about their risks and
interpretation.
Once
the type of DI has been established, the appropriate treatment can be selected. In the
case of pituitary (central/neurogenic) DI, the treatment of choice is
usually a synthetic form of antidiuretic hormone known as DDAVP. It can be taken by
injection, by nasal spray or by tablet at whatever dose and/or frequency is necessary to
completely eliminate the increase in urination, thirst and drinking without allowing
periodic 'breakthrough" or 'escape'. The only 'toxic' side affect is water
intoxication and it is rare provided the patient remembers to drink fluids only when he or
she is truly thirsty. Occassionally, other forms of treatment such as chlorpropamide
may be used in preference to DDAVP.
Patients
with dipsogenic DI or other forms of primary polydipsia cannot take DDAVP
in the usual way because they invariably develop water intoxication during treatment. In
this situation, the only thing that can be done is to voluntarily limit fluid intake as
much as possible and, sometimes, to take a single small dose of DDAVP at bedtime to reduce
the frequency of awakenings to urinate.
In
patients with nephrogenic DI, treatment with DDAVP or chlorpropamide is
ineffective. If the underlying cause of the DI cannot be eliminated, the signs and
symptoms of DI usually can be reduced by decreasing the amount of salt in the diet and
taking certain diuretics which have a paradoxical antidiuretic effect in this disease.
As in the case of the
diagnostic tests, treatments should be undertaken only under the supervision of a
physician knowledgeable about their use and potential side effects.